RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Direct Answers, Evidence Quality Included
Questions readers actually search for, answered plainly — with a note on how strong (or thin) the underlying evidence is for each one.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a), triggering a discrete pulse of growth hormone release from the pituitary without meaningfully raising cortisol or prolactin. It has never been approved as a drug for any human indication. Its one controlled human trial, in postoperative bowel-surgery patients, did not meet its primary endpoint [3].
What does ipamorelin do for you?
Mechanistically, it triggers a short-lived pulse of growth hormone about 40 minutes after dosing, with a roughly two-hour half-life [4]. What that translates to functionally in humans is not established by controlled trial data — the one trial designed to test a functional outcome (faster return of gut function after surgery) found no statistically significant benefit over placebo [3]. Effects described in research-use communities — sleep, recovery, body composition — are anecdotal and unverified, not confirmed by the clinical literature.
What are the risks of ipamorelin?
The mechanistic risks include theoretical concerns around IGF-1 elevation and malignancy, unpredictable glycemic effects in people with diabetes or insulin resistance, and a class-level cardiovascular signal — a related GHS-R1a agonist (not ipamorelin itself) produced dose-dependent heart-muscle damage in a 28-day rat study [2]. No long-term human safety study of ipamorelin exists, and research-grade material sold outside clinical trials carries no verified purity or identity assurance.
What is KPV peptide?
KPV is a three-amino-acid tripeptide (lysine-proline-valine) corresponding to the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH's anti-inflammatory activity in animal models while lacking the pigment-darkening effect of the full hormone. It has never been tested in a published human clinical trial [6][7][8][9][10].
What does KPV peptide do?
In cell culture and mouse colitis models, KPV suppresses NF-kB and MAP-kinase inflammatory signaling and reduces pro-inflammatory cytokine production, reducing the severity of chemically induced colitis in mice [8][9]. Recent work has focused on nanoparticle and hydrogel delivery systems to keep the peptide intact long enough to act, since it is rapidly broken down in its free form [6][7]. All of this evidence is preclinical; what KPV does in a human body has not been tested.
What is KPV peptide good for?
Based on the published literature, KPV's studied use is narrow: reducing inflammation and tissue damage in mouse models of colitis, with a mechanism (PepT1-mediated uptake, NF-kB/MAPK suppression) that does not depend on an intact melanocortin receptor [9]. Broader marketing claims about gut health, skin, or general anti-inflammatory benefit in people extend well past what this mouse-model literature actually supports.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), modified to resist enzymatic breakdown. It is FDA-approved (since 2010) specifically to reduce excess visceral abdominal fat in HIV-infected adults with antiretroviral-associated lipodystrophy [16]. It has no approved indication outside that population.
How does tesamorelin work?
It binds the GHRH receptor on pituitary somatotroph cells, stimulating the body's own pulsatile release of growth hormone, which in turn raises IGF-1 and promotes lipolysis preferentially in visceral fat [14]. In its pivotal 26-week trial, this reduced visceral adipose tissue by 15.2% versus a 5.0% increase with placebo [16]; a 2026 meta-analysis of five trials confirmed the visceral-fat and liver-fat reductions while finding an increase, not a decrease, in lean body mass [11].
Will tesamorelin help me lose belly fat?
This site does not answer questions about what a specific individual should expect or do — that requires a licensed clinician. What the trial evidence shows is narrower than the question: tesamorelin reduced visceral (deep abdominal) fat in randomized trials of HIV-infected adults with lipodystrophy [11][13][15][16], and the benefit did not persist after participants stopped dosing [15]. Those trials did not enroll a general population seeking cosmetic fat loss, so extending the result to that use is an extrapolation the data does not directly support.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that activates two hormone receptors simultaneously — GIP and GLP-1 — earning it the informal "twincretin" label. It is FDA-approved for type 2 diabetes (2022) and, separately, for chronic weight management [19].
How does tirzepatide work?
By engaging both the GIP and GLP-1 receptors, it enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying — the shared mechanism that drives both its efficacy and its gastrointestinal side effects. In vitro work shows it engages the GIP receptor more strongly than the GLP-1 receptor and signals through GLP-1R in a biased fashion favoring cAMP over beta-arrestin recruitment, a proposed mechanistic basis for its larger effect sizes relative to selective GLP-1 agonism. In a head-to-head trial, it produced -20.2% mean weight loss versus -13.7% for a selective GLP-1 comparator over 72 weeks [18].
What is tirzepatide used for?
Its FDA-approved uses are type 2 diabetes mellitus and chronic weight management in adults with obesity or overweight plus a weight-related condition [19]. In clinical trials it has also been studied head-to-head against a selective GLP-1 agonist for both weight loss [18] and glycemic control [22], outperforming it on both measures. It is a prescription medicine; this page describes published trial data, not a recommendation for any individual.